摘要
目的:结合生产者对药品的整体认识程度,以及药品本身特点,具体讨论缺陷药品生产者是否免责,明晰法律完善方向。方法:通过研究药品研究缺陷、生产缺陷、警示缺陷、使用缺陷的特点以及对药品生产者提出的要求,对"药品投入流通时缺陷尚不存在"是否免责,进行深入剖析。结果与结论:鉴于药品本身的特征及《侵权责任法》的发布,免责事由"投入流通时缺陷尚不存在"应作限制性解释。
Objective:The article intended to specifically discuss the producers of defects drugs whether can be exempted from liability and put forward suggestions for legislation improvement,in combination of the overall awareness of the producers about drugs and drug characteristics.Method:Through the study of pharmaceutical research defects,manufacturing defects,warning defects,the use defects,and the requirements for drug producers,if the producers should be disclaimer from 'No Defects When Drugs into Circulation' was analyzed.Result & Conclusion:'No Defects When Drugs into Circulation' should be a restrictively interpreted according to the drug characteristic and issue of Tort liability law.
出处
《中药与临床》
2012年第5期35-38,共4页
Pharmacy and Clinics of Chinese Materia Medica
关键词
缺陷药品
侵权
免责事由
责任
Defective drugs
tort
exemption excuses
liability
